The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.
The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Anti-obesity Drugs Market forecast from 2018-2028
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action: • Incretion mimetics/GLP-1 agonists • SNDRIs • Lipase Inhibitors • Serotonin receptor agonists • Sympathomimetic-GABA receptor agonists • Sympathomimetics
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy: • Long-term Drugs • Short-term Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs: • Innovator • Generic Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC: • Prescription Drugs • OTC
• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs: • Saxenda • Contrave/Mysimba • Belviq • Qysmia • Xenical • Alli
• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets: • US • Japan • EU5: Germany, France, Spain, Italy, UK • BRIC: Brazil, Russia, China, India • RoW
Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs
• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market: • Eisai/Arena • GlaxoSmithKline (GSK) • Novo Nordisk • Orexigen/Takeda • Roche • Teva • Vivus
• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
• This report gives an overview of pricing and reimbursement in the US and EU.
• This report provides a SWOT Analysis of the global anti-obesity drugs market.
Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Why You Should Read This Report 1.2 How This Report Delivers 1.3 Key Questions Answered by This Analytical Report: 1.4 Who is This Report for? 1.5 Methodology 1.5.1 Primary Research 1.5.2 Secondary Research 1.5.3 Market Evaluation & Forecasting Methodology 1.6 Frequently Asked Questions 1.7 Associated Reports 1.8 About Visiongain
2. Introduction to Obesity 2.1 What is Obesity? 2.1.1 Types of obesity 2.1.1.1 Central Obesity / Android Type 2.1.1.2 Peripheral Obesity/ Gynoid Type 2.2 What are the causes and risk factors of obesity? 2.2.1 Energy Imbalance 2.2.2 Genetic Predisposition 2.2.3 Unhealthy Diet 2.2.4 Health Conditions and Medicines 2.2.5 Emotional Factors 2.2.6 Age 2.2.7 Pregnancy 2.2.8 Lack of Sleep 2.2.9 Smoking 2.3 Obesity Measurement 2.3.1 BMI 2.3.2 Waist circumference 2.3.3 Index of Central Obesity 2.3.4 Bioelectrical Impedance Analysis 2.3.5 New Approaches/Techniques 2.4 Epidemiology of Obesity 2.4.1 Epidemiology by Geography 2.4.2 Epidemiology by Country 2.4.3 Historical Prevalence in Major Markets 2.4.4 Forecast of Obesity Prevalence in Major Markets 2.5 Humanistic and Economic Burden 2.5.1 Mortality 2.5.2 Morbidity 2.5.2.1 Disability-adjusted life year (DALY) 2.5.2.2 Years Lost due to Disability (YLD) 2.5.2.3 Years of Life Lost (YLL) 2.5.3 Economic Impact 2.6 Obesity: Prevention and Treatment 2.6.1 Lifestyle changes 2.6.2 Pharmacotherapy 2.6.3 Other treatments
3. Introduction to the Global Anti-obesity Drugs Market 3.1 Market Structure 3.2 Market Definition and Scope 3.3 Classification by Mechanism of Action 3.3.1 Incretin Mimetics/GLP-1 Agonists 3.3.2 Lipase Inhibitors 3.3.3 Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors 3.3.4 Serotonin Receptor Agonists 3.3.5 Sympathomimetics 3.3.6 Sympathomimetic-GABA Receptor Agonists 3.3.7 Others 3.4 Classification by Innovator or Generics Drugs 3.4.1 Innovator Drugs 3.4.2 Generics Drugs 3.5 Classification by Prescription or OTC drugs 3.5.1 Prescription drugs 3.5.2 OTC drugs 3.6 Classification by Duration of Therapy 3.6.1 Short-term drugs 3.6.2 Long-term drugs
4. Global Anti-obesity Drugs Market 2018-2028 4.1 Global Anti-obesity Drugs Market 2017 4.2 Global Anti-obesity Drugs Market Forecast 2017-2028 4.3 Global Anti-obesity Drugs by Mechanism of Action 4.3.1 Global Anti-obesity Drugs by Mechanism of Action: Market Forecasts 2018-2028 4.3.1.1 Incretin mimetics/GLP-1 Agonists: Market Forecasts 2018-2028 4.3.1.2 Lipase Inhibitors: Market Forecasts 2018-2028 4.3.1.3 Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI): Market Forecasts 2018-2028 4.3.2 Serotonin Receptor Agonists: Market Forecasts 2018-2028 4.3.2.1 Sympathomimetic-GABA Receptor Agonists: Market Forecasts 2018-2028 4.3.2.2 Sympathomimetics: Market Forecasts 2018-2028 4.3.2.3 Others: Market Forecasts 2018-2028 4.3.3 Global Anti-obesity Drugs Market Forecasts by Mechanism of Action: Market Share 2018-2028 4.4 Global Anti-obesity Drugs Market by Innovator and Generics Drugs 4.4.1 Global Anti-obesity Drugs by Innovator Drugs and Generics: Market Forecasts 2018-2028 4.4.1.1 Innovator Drugs: Market Forecasts 2018-2028 4.4.1.2 Generics: Market Forecasts 2018-2028 4.4.2 Global Anti-obesity Drugs Market Forecast by Innovator Drugs and Generics: Market Share 2018-2028 4.5 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 4.5.1 Global Anti-obesity Drugs Market by Prescription and OTF Drugs: Market Forecast 2018-2028 4.5.1.1 Prescription Drugs: Market Forecasts 2018-2028 4.5.1.2 OTC Drugs: Market Forecasts 2018-2028 4.5.2 Global Anti-obesity Drugs Market Forecast by Prescription and OTC Drugs: Market Share 2018-2028 4.6 4.6 Global Anti-obesity Drugs Market by Duration of Therapy 4.6.1 Global Anti-obesity Drugs Market by Duration of Therapy: Market Forecast 2017-2028 4.6.1.1 Short-term Anti-obesity Drugs: Market Forecasts 2018-2028 4.6.1.2 Long-term Anti-obesity Drugs: Market Forecasts 2018-2028 4.6.2 Global Anti-obesity Drugs Market Forecast by Duration of Therapy: Market Share 2017-2028 4.7 Overall Global Anti-obesity Drugs Market Drivers, Restraints and Trends
5. Leading Anti-obesity Drugs 5.1 Snapshot of Anti-obesity Drugs 5.2 Innovator Drugs 5.2.1 Saxenda 5.2.1.1 Saxenda Drug Profile 5.2.1.2 Saxenda Historical Sales 5.2.1.3 Saxenda Forecast 2018-2028 5.2.1.4 Saxenda Sales by Geography, 2017 5.2.2 Contrave / Mysimba 5.2.2.1 Contrave Drug Profile 5.2.2.2 Contrave Historical Sales 5.2.2.3 Contrave Forecast 2018-2028 5.2.2.4 Contrave Sales by Geography, 2017 5.2.3 Belviq 5.2.3.1 Belviq Drug Profile 5.2.3.2 Belviq Historical Sales 5.2.3.3 Belviq Forecast 2018-2028 5.2.3.4 Belviq Sales by Geography, 2017 5.2.4 Qysmia 5.2.4.1 Qysmia Drug Profile 5.2.4.2 Qysmia Historical Sales 5.2.4.3 Qysmia Forecast 2018-2028 5.2.4.4 Qysmia Sales by Geography, 2017 5.2.5 Xenical and Alli 5.2.5.1 Xenical and Alli Historical Sales 5.2.5.2 Xenical and Alli Sales by Geography, 2017 5.2.5.3 Xenical and Alli Forecast 2018-2028 5.2.6 Cametor/Oblean 5.2.7 Lomaira 5.3 Generics 5.3.1 Orlistat 5.3.1.1 Orlistat Historical Sales 5.3.2 Sibutramine 5.3.2.1 Sibutramine Historical Sales 5.3.3 Adipex 5.3.3.1 Adipex Historical Sales 5.3.4 Phentermine 5.3.4.1 Phentermine Historical Sales
6. Leading National Markets Forecast 2018-2028 6.1 Geographical Breakdown of Global Anti-obesity Drugs Market, 2017 6.1.1 Regional Breakdown of Global Anti-obesity Drugs Market, 2017 6.1.2 Country Breakdown of Global Anti-obesity Drugs Market, 2017 6.2 Regional Forecast of Global Anti-obesity Drugs Market, 2018-2028 6.3 US Anti-obesity Drugs Market 6.3.1 US Anti-obesity Drugs: Market Forecasts 2018-2028 6.4 Japan Anti-obesity Drugs Market 6.4.1 Japan Anti-obesity Drugs: Market Forecasts 2018-2028 6.5 EU5 Anti-obesity Drugs Market, 2017 6.5.1 EU5 Anti-obesity Drugs: Market Forecast 2018-2028 6.5.1.1 The UK Anti-obesity Drugs: Market Forecasts 2018-2028 6.5.1.2 Germany Anti-obesity Drugs: Market Forecasts 2018-2028 6.5.1.3 France Anti-obesity Drugs: Market Forecasts 2018-2028 6.5.1.4 Italy Anti-obesity Drugs: Market Forecasts 2018-2028 6.5.1.5 Spain Anti-obesity Drugs: Market Forecasts 2018-2028 6.6 BRIC Anti-obesity Drugs Market, 2017 6.6.1 BRIC Anti-obesity Drugs: Market Forecasts 2018-2028 6.6.1.1 China Anti-obesity Drugs: Market Forecasts 2018-2028 6.6.1.2 India Anti-obesity Drugs: Market Forecasts 2018-2028 6.6.1.3 Brazil Anti-obesity Drugs: Market Forecasts 2018-2028 6.6.1.4 Russia Anti-obesity Drugs: Market Forecasts 2018-2028
7. Research and Development for Treating Obesity 7.1 Novel Mechanism of Action of Pipeline Drugs 7.2 Active Pipeline Molecules 7.3 Promising Potential Pipeline Molecules 7.3.1 Phase III Molecules 7.3.1.1 BTI-320 7.3.2 Phase II Molecules 7.3.2.1 Oxyntolong 7.3.2.2 Antisense FGFR4 oligo, Verva 7.3.2.3 S-237648 7.3.2.4 Setmelanotide 7.3.2.5 Bupropion + zonisamide SR 7.3.2.6 Semaglutide 7.3.2.7 LIK066 7.3.2.8 Tesofensine 7.3.2.9 LIPO-202 7.3.2.10 Canagliflozin and Phentermine 7.3.2.11 OBEP-100 7.3.2.12 Efpeglenatide 7.3.2.13 EMP16 7.3.2.14 MEDI-0382
8. Pricing and Reimbursement Overview 8.1 US 8.2 EU 8.3 Payers Perspective
9. Qualitative Analysis of the Global Anti-obesity Drugs Market 9.1 SWOT Analysis, 2017 10. Leading Companies in Global Anti-obesity Drugs Market, 2017 10.1 Novo Nordisk 10.1.1 Obesity Care – To Establish its presence 10.2 Orexigen/Takeda 10.2.1 Collaboration Agreement with Takeda Pharmaceutical Company Limited 10.2.2 Collaboration Agreement with Valeant 10.3 Arena/Eisai 10.3.1 Collaboration Agreement with Eisai Co., Ltd. 10.3.2 Collaboration Agreement with Other Companies 10.4 F. Hoffmann-La Roche Ltd. 10.5 Vivus 10.6 Teva 10.7 GlaxoSmithKline (GSK)
11. Conclusions Associated visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain report evaluation form
List of Tables Table 2.1: WHO BMI Cut Off Points Table 2.2 Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk Table 3.1 Mechanism of Action of Innovator Drugs for the treatment of Obesity Table 3.2 List of Innovator Drugs for the treatment of Obesity Table 3.3 List of Prescription Drugs for the treatment of Obesity Table 3.4 Long-term Prescription Drugs for the treatment of Obesity Table 4.1 Global Anti-obesity Drugs Market by Markets: Revenue ($m), and Market Share (%), 2017 Table 4.2 Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.3 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.4 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%) Table 4.5 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.6 List of Active GLP-1 agonists in Clinical Pipeline Table 4.7 Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.8 List of Active SNDRI agonists in Clinical Pipeline Table 4.9 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.10 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.11 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.12 Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.13 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.14 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Market Share (%) Table 4.15 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.16 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: AGR (%) Table 4.17 Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.18 Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.19 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%) Table 4.20 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.21 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%) Table 4.22 Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.23 Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.24 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%) Table 4.25 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.26 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%) Table 4.27 Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 4.28 Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.1 Saxenda Drug Profile Table 5.2 Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.3 Contrave Drug Profile Table 5.4 Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.5 Belviq Drug Profile Table 5.6 Belviq Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.7 Qysmia Drug Profile Table 5.8 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.9 Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.1 Global Anti-obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2017 Table 6.2 Global Anti-obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2017 Table 6.3 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.4 Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%) Table 6.5 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028 Table 6.6 US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.7 U.S. Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.8 U.S. Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.9 US Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.10 US Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.11 Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.12 Japan Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.13 Japan Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.14 Japan Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.15 Japan Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.16 EU5 Anti-obesity Drugs Market by Region: Market Size ($m) and Share (%), 2017 Table 6.17 EU5 Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.18 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%) Table 6.19 EU5 Anti-obesity Drugs Market Forecast by Region: AGR (%) 2017-2028 Table 6.20 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.21 UK Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.22 UK Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.23 UK Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.24 UK Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.25 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.26 Germany Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.27 Germany Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.28 Germany Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.29 Germany Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.30 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.31 France Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.32 France Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.33 France Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.34 France Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.35 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.36 Italy Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.37 Italy Anti-obesity Drugs Market Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.38 Italy Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.39 Italy Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.40 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.41 Spain Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.42 Spain Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.43 Spain Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.44 Spain Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.45 Anti-obesity Drugs Market in the BRIC Region: Market Size ($m) & Share 2017 (%) Table 6.46 BRIC Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.47 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.48 China Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.49 China Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.50 China Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.51 China Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.52 India Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.53 India Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.54 India Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.55 India Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.56 India Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.57 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.58 Brazil Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.59 Brazil Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.60 Brazil Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.61 Brazil Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.62 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 6.63 Russia Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.64 Russia Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.65 Russia Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 6.66 Russia Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 7.1 Active Pipeline Molecules under Development for Treating Obesity Table 10.1: Innovator Drugs’ Originator-Licensee Information Table 10.2 Novo Nordisk A/S: Overview Table 10.3 Novo Nordisk: List of Active Clinical Pipeline Molecules Table 10.4 Orexigen: Overview Table 10.5 Arena: Overview Table 10.6 Roche: Overview Table 10.7 Vivus: Overview Table 10.8 Teva: Overview Table 10.9 Vivus: Overview
List of Figures Figure 2.1 Prevalence of Obesity by WHO region, ages 18+, Both sexes, 2014 Figure 2.2 Prevalence of Overweight, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014 Figure 2.3 Prevalence of Obesity, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014 Figure 2.4 Prevalence of Obesity in OECD 32 Countries – population aged 15 years and over, 2013 or nearest year Figure 2.5 Prevalence of Obesity in G7 and BRIC Countries – population aged 15 years and over, 2012 or nearest year, men, women, both sexes Figure 2.6 Age-Standardized Obesity Prevalence Rate in Major Markets – Population aged 15 years and over, 1973-2012 Table 2.7 Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2017-2028, million, CAGR% (2017-2028) Figure 2.8 Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015 Figure 2.9 DALY’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015 Figure 2.10 YLD’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015 Figure 2.11 YLL’s due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015 Figure 3.1 Global Anti-obesity Drugs Market Segmentation Overview Figure 3.2 Anti-Obesity Drugs Classification by Mechanism of Action, 2017 Figure 4.1 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017 Figure 4.2 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017 Figure 4.3 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017 Figure 4.4 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017 Figure 4.5 Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 4.6 Global Anti-obesity Drugs Market by Mechanism of Action 2017, Revenue ($m) Figure 4.7 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017 Figure 4.8 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), Global AGR (%) Figure 4.9 Global Anti-obesity Drugs Market by Mechanism of Action 2017 and 2028: Revenue ($m), CAGR (%) 2017-2028 Figure 4.10 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%) Figure 4.11 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.12 Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.13 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.14 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.15 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.16 Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.17 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.18 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Market Share (%) Figure 4.19 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2022 Figure 4.20 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2028 Figure 4.21 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue ($m), 2017 Figure 4.22 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017 Figure 4.23 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), Global AGR (%) Figure 4.24 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%) Figure 4.25 Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%) Figure 4.26 Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.27 Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.28 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%) Figure 4.29 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2022 Figure 4.30 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2028 Figure 4.31 Global Anti-obesity Drugs Market by Prescription and OTC Drugs, Revenue 2017 ($m) Figure 4.32 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017 Figure 4.33 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), Global AGR (%) Figure 4.34 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%) Figure 4.35 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%) Figure 4.36 Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.37 Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.38 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%) Figure 4.39 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017 Figure 4.40 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2028 Figure 4.41 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue ($m), 2017 Figure 4.42 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017 Figure 4.43 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%) Figure 4.44 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%) Figure 4.45 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%) Figure 4.46 Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.47 Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%) Figure 4.48 Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Market Share (%) Figure 4.49 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017 Figure 4.50 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2028 Figure 4.51 Global Anti-obesity Drugs Market: Drivers and Restraints Figure 4.52 Trends in Global Anti-obesity Drugs Market Figure 5.1 Leading Anti-obesity Drug Sales, Revenue ($m), 2017 Figure 5.2 Leading Anti-obesity Drug Sales, Market Share (%), 2017 Figure 5.3 Anti-obesity Drugs Sales Forecast, Market Share (%), 2028 Figure 5.4 Leading Anti-obesity Drugs: Historical Revenue ($m), 2012-2017 Figure 5.5 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2017 Figure 5.6 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2028 Figure 5.7 Saxenda Global Sales: Revenue ($million), 2015-2016 Figure 5.8 Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%) Figure 5.9 Saxenda Sales by Geography: Market Share (%), 2017 Figure 5.10 Contrave Global Sales: Revenue ($million), 2014-2016 Figure 5.11 Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%) Figure 5.12 Contrave Sales by Geography: Market Share (%), 2017 Figure 5.13 Belviq Global Sales: Revenue ($million), 2013-2016 Figure 5.14 Belviq Sales Forecast 2017-2028: Revenue ($million), AGR (%) Figure 5.15 Belviq Sales by Geography: Market Share (%), 2017 Figure 5.16 Qysmia Global Sales: Revenue ($m), 2013-2016 Figure 5.17 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%) Figure 5.18 Qysmia Sales by Geography: Market Share (%), 2017 Figure 5.19 Xenical Global Sales: Revenue ($million), 2011-2016 Figure 5.20 Alli Global Sales: Revenue ($million), 2011-2016 Figure 5.21 Xenical Sales by Geography: Market Share (%), 2017 Figure 5.22 Alli Sales by Geography: Market Share (%), 2017 Figure 5.23 Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%) Figure 5.24 Global Anti-obesity Generics Market by Individual Compound: Market Share (%), 2017 Figure 5.25 Orlistat Global Sales: Revenue ($m), 2011-2016 Figure 5.26 Sibutramine Global Sales: Revenue ($m), 2012-2017 Figure 5.27 Adipex Global Sales: Revenue ($m), 2012-2017 Figure 5.28 Phentermine Global Sales: Revenue ($m), 2012-2017 Figure 6.1 Global Anti-obesity Drugs Market Segmentation by Region/Country Figure 6.2 Global Anti-obesity Drugs Market by Region: Revenue ($m), 2017 Figure 6.3 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017 Figure 6.4 Global Anti-obesity Drugs Market by Country: Revenue ($m), 2017 Figure 6.5 Global Anti-obesity Drugs Market by Country: Market Share (%), 2028 Figure 6.6 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2017-2028 Figure 6.7 Global Anti-obesity Drugs Market Forecast by Region 2017, 2022, 2028: Revenue ($m), CAGR 2017-2028 (%) Figure 6.8 Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%) Figure 6.9 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028 Figure 6.10 Global Anti-obesity Drugs Market by Region: Market Share (%), 2017 Figure 6.11 Global Anti-obesity Drugs Market by Region: Market Share (%), 2022 Figure 6.12 Global Anti-obesity Drugs Market by Region: Market Share (%), 2028 Figure 6.13 US Anti-obesity Drugs Market by Mechanism of Action: Market Share %, 2017 Figure 6.14 US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 6.15 Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 6.16 EU5 Anti-obesity Drugs Market by Region: Global Market Share (%), 2017 Figure 6.17 EU5 Anti-obesity Drugs Market by Region: Market Share (%), 2017 Figure 6.18 EU5 Anti-obesity Drugs Market Forecast by Region 2017-2028: Revenue ($m), AGR (%) Figure 6.19 EU5 Anti-obesity Drugs Market by Region 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%) Figure 6.20 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%) Figure 6.21 EU5 Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028 Figure 6.22 EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2023 Figure 6.23 EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028 Figure 6.24 EU5 Global Anti-obesity Drugs Market Forecast by Region: AGR (%), 2017-2028 Figure 6.25 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.26 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.27 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.28 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.29 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.30 BRIC Anti-obesity Drugs Market by Region: Global Market Share 2017 (%) Figure 6.31 BRIC Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 6.32 BRIC Anti-obesity Drugs Market Forecast 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%) Figure 6.33 BRIC Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028 Figure 6.34 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2017 Figure 6.35 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028 Figure 6.36 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028 Figure 6.37 India Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028 Figure 6.38 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028 Figure 6.39 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028 Figure 7.1 Anti-obesity Clinical Pipeline Segmentation by Phase, 2017 Figure 7.2 Anti-obesity Pipeline Segmentation by Mechanism of Action, 2017 Figure 9.1 SWOT Analysis of the Global Anti-obesity Drugs Market Figure 10.1 Global Anti-obesity Drugs Market by Company: Revenue ($m) Figure 10.2 Global Anti-obesity Drugs Market by Company 2017: Market Share (%) Figure 10.3 Novo Nordisk’s 20-year R&D journey in Obesity - Milestones of Saxenda Figure 11.1 Global Anti-obesity Drugs Market by Region: Share (%), 2017 and 2028
ADial Pharmaceuticals AEMPS AIFA HAS Akrimax Pharmaceuticals American Medical Association Arena Pharmaceuticals AstraZeneca Biophytis Boehringer Ingelheim Boston Therapeutics Diasome Eisai EMEA Empros Pharma FDA G-BA GenePreDiT GlaxoSmithKline (GSK) Hanmi Ildong Pharmaceuticals Intarcia Therapeutics Ionis Pharmaceuticals Janssen Pharmaceuticals KT&G Life Sciences KVK Tech Kwang Dong Medivation Medlab Clinical Neothetics NGM Biopharmaceuticals NICE SMC Novartis Novo Nordisk OPKO Health Orexigen Rhythm Pharmaceuticals Roche Saniona Shionogi & Co., Ltd Takeda Teva Valeant Pharmaceuticals Virtici Vivus World Health Organization (WHO) Xenetic Biosciences Zafgen
Download sample pages
Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028
Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain
It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.
“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain
Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.
“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain
The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.
